Swedish company Corline Systems AB, a maker and distributor of CHS, a unique heparin coating technology for use on Medical Devices and for Regenerative Medicine, today announced that it has signed an agreement exclusively licensing its technology within a specified Field-of-Use to one of the major US medical device manufacturers. The agreement allows use of Corline’s CHS technology on a device for patients that undergo routine dialysis treatments.

The CHS coated product is planned for market launch during mid 2011 and the agreement includes customary but non-disclosed milestone payments, royalty fees and payments for Corline’s on-going supply of its proprietary coating reagents.

“This is a break-through deal for Corline and this will be the first product incorporating our CHS technology to be launched on the important US market”, comments CEO Henrik Nittmar.

End-stage renal disease, ESDR, is a severely debilitating disease that affects many people - 500,000 or more in the US alone according to NIH/NIDDK (2006). More than 350,000 of these patients undergo dialysis treatments and the yearly cost for the US ESDR program exceeds $33 bn.

The equipment and device market for this patient group is a very important part of the US overall medical device market and a number of the major US players are servicing it, and obviously a large number of technology providers and suppliers rely on it for revenues. Through this agreement, Corline will join that group.

“We are very proud to have been chosen by a major US medical device manufacturer as technology licensor and supplier. It will make us work even harder to achieve our stretched goals, market-wise and with our technology innovation efforts. This relationship will help develop Corline as an organization in a highly positive way, but also shows potential customers around the world that our technology truly stands out compared to the alternatives. Many medical devices need surface treatment to increase their biocompatibility and, of course, we see this agreement as the start of something very exciting”, concludes CEO Henrik Nittmar.